<DOC>
	<DOCNO>NCT00258076</DOCNO>
	<brief_summary>The objective study estimate exposure hormone norelgestromin , norgestrel , ethinyl estradiol bloodstream healthy female volunteer across multiple commercial lot ORTHO EVRAÂ® ( transdermal contraceptive patch ) compare data historical hormonal exposure data one ORTHO EVRAÂ® clinical development lot .</brief_summary>
	<brief_title>A Study Evaluate Hormone Exposure From Multiple Commercial Lots ORTHO EVRA ( Transdermal Contraceptive Patch )</brief_title>
	<detailed_description>This multicenter , open-label , randomize , partially-balanced , incomplete block design study consist pre-treatment phase ( screening period last 21 day ) , open-label treatment phase ( three 7-day treatment period separate 21-day washout ) , post-treatment phase ( follow-up early withdrawal visit ) . Total participation study approximately 67 day . Approximately 52 subject enrol . The study population comprise healthy woman , age 18 45 year inclusive , weigh least 110 pound , body mass index ( BMI ) 16 29.9 kg per meter square . An ORTHO EVRA® patch 1 13 select commercial lot apply buttock subject worn 7 day . Patches apply Days 1 , 29 , 57 investigator designate study unit personnel . Each patch wear upper outer quadrant buttock , 3 patch necessarily place exact position . The investigator designate study unit personnel remove patch Days 8 , 36 , 64 evaluate adhesion patch removal . Subjects confine study unit blood sample collection determination NGMN , NG , EE serum concentration . Blood sample collect ( via venipuncture ) immediately specify time point patch application . Pharmacokinetic parameter NGMN , NG , EE , include Cmax , tmax , AUC treatment estimate standard method . Safety assess throughout study , base adverse event change physical gynecologic examination ( include breast examination ) , vital sign , electrocardiogram ( ECGs ) , clinical laboratory test result . Three 7-day treatment period , separate 21-day washout , follow : Each ORTHO EVRA® patch worn buttock ( upper outer quadrant ) 7 day . Twenty one day complete treatment , subject cross next treatment 7 day . The patch apply upper outer quadrant buttock , necessarily exact spot .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Ortho Evra</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Subjects pregnant ( demonstrated negative pregnancy test screen admission treatment period ) complete last term pregnancy least 60 day admission visit confirm good health determine medical history , physical examination ( include vital sign ) , gynecologic examination ( include breast examination ) , laboratory test result history regular menstrual cycle , weigh least 110 pound ( 50 kilogram ) , body mass index ( BMI ) 16 29.9 kg per meter square , hematocrit least 36 % screening , ferritin level lower limit normal nonsmoker use tobacco product least 6 month study admission agree use prescription nonprescription medication duration study , subject male partner surgically sterile , agree continue use nonhormonecontaining intrauterine device ( IUD ) one follow method doublebarrier contraception participation study : condom foam , diaphragm gel , cervical cap gel . Subjects history presence disorder commonly accept contraindication sex hormonal therapy include , limited : deep vein thrombophlebitis thromboembolic disorder , cerebral vascular coronary artery disease , chronic untreated hypertension migraine , benign malignant liver tumor develop use oral contraceptive estrogencontaining product , know suspected estrogendependent neoplasia presence disorder commonly accept contraindication combine oral contraceptive therapy include , limited : undiagnosed abnormal vaginal bleeding , neurovascular lesion eye serious visual disturbance , impairment liver function , liver disease , kidney disease currently pregnant breast feeding , evidence cervical dysplasia ( document Pap smear within 6 month randomization ) use steroid hormonal therapy within 30 day first admission visit , receive Depo Provera® injection within 6 month first admission visit , receive Lunelle® injection within 60 day first admission visit , currently Norplant® place , removal Norplant within 60 day first admission visit , use steroid hormonecontaining intrauterine device ( IUD ) within 3 month randomization elevate blood pressure ( sit systolic BP &gt; 140 mm Hg and/or diastolic BP &gt; 90 mm Hg ) history presence hypersensitivity response topical application ( bandage , surgical tape , etc . ) active inflammation skin ( dermatitis ) skin condition ( dermatosis ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Transdermal contraception</keyword>
	<keyword>contraceptive</keyword>
	<keyword>hormonal , steroid contraception</keyword>
	<keyword>ethinyl estradiol</keyword>
	<keyword>progesterone</keyword>
	<keyword>EVRA</keyword>
</DOC>